

PFIZER'S CENTERS FOR THERAPEUTIC INNOVATION REQUESTS PROPOSALS FOR THERAPEUTIC TARGETS

Internal Deadline: June 21, 2021*

Pfizer's Centers for Therapeutic Innovation (CTI) is a unique joint drug discovery model focused on collaborating with leading academic centers to translate and transform concepts into breakthroughs that change patients' lives.

The CTI 2021 Call for Proposals (CFP) is focused on identifying novel therapeutic opportunities in the areas outlined below with application in Pfizer's core research focus areas: oncology, inflammation & immunology, internal medicine and rare diseases.

Northwestern can facilitate discussion with Pfizer prior to drafting a proposal to help ensure the ideas are aligned with Pfizer's interest.

CTI Collaborations Include:

- Funding for project-specific research
- Hands-on collaboration from dedicated Pfizer drug-development experts
- Access to scientific/technological expertise and infrastructure at Pfizer
- Potential for in-licensing by Pfizer, which would include milestone and royalty payments
- Publishing rights

Submission Process:

NewCures can facilitate early discussions with Pfizer prior to submission. Interested PIs should contact [Caroline Ko](#), Project Leader of NewCures, as soon as possible. Together with Feinberg Corporate Relations, we will support the PIs to prepare the submission.

Submission entails a non-confidential, 2-3 page Pre-Proposal application; the Pre-Proposal template can be found at the [NewCures](#) website. At a high level, the Pre-Proposal should provide an overview of the target, mechanism, evidence for disease linkage, the proposed therapeutic drug, and suggest how the therapeutic hypothesis could be tested in the clinic. Pre-Proposals submitted to Pfizer CTI will be reviewed on a rolling basis.

Non-Confidential Pre-Proposals must be submitted to newcures@northwestern.edu by June 21, 2021.